Medworxx Inc. (“Medworxx”) (TSXV:MWX), a leader in Clinical Utilisation Review (CUR) solutions, announced today that NHS England has selected Medworxx and three other patient flow solution providers as CUR Preferred Bidders. In 2014 NHS England introduced a Commissioning for Quality and Innovation scheme (CQUIN) to require mandatory adoption of CUR as a core capability to ensure the provision of safe and cost effective care. After an extensive RFP process, NHS England named four vendors to support CUR technology for specialised services and critical care. This announcement confirms that NHS England and preferred vendors now have a Framework Agreement in place and allows NHS Trusts to contract directly with vendors from the framework without repeating the usual procurement processes using CQUIN funds. The Framework Agreement also confirms that only products from these four vendors will be recognized for CQUIN funding. The framework can also be used by all other NHS provider and commissioner organisations in England.

"Although the CQUIN funds have been available since April 1st, the Hospital Trusts have been waiting for the Framework Agreement to be finalized before procuring software. With this now completed the expectation is that Hospital Trusts will now start to license and deploy CUR solutions. We expect to see increased customer demand in the near future,” said Dan Matlow, CEO and President, Medworxx.

This Framework Agreement puts Medworxx in a strong position— 26 UK sites have used the Medworxx solution in a diagnostic capacity and Medworxx is currently supporting 5 embedded UK customers. Medworxx is the leading clinical utilization vendor in the UK and Canada and has a combined international total of over 30,600 licensed beds using Medworxx patient flow software.

About Medworxx
Medworxx delivers health information technology solutions to over 350 hospitals internationally; including Canada, United States, United Kingdom, France and Australia. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria —flagship of Medworxx Patient Flow that includes electronic bed management and independent assessment components—currently serves over 32% of the acute-care beds in Canada, and rapidly increasing number of Trusts and CCGs in the UK. Founded in 2004, Medworxx Inc. is based in Toronto, ON, and publicly traded on the TSX Venture
Exchange: MWX.
Visit: www.medworxx.com

Disclaimer

The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.